Sarcopenia in Older Patient With Prostate Cancer, Prevalence and Incidence After Androgen Deprivation Therapy

NCT04484246 | Completed

• 1 other identifier: 2019-35
• Study Type: observational
• Target: 112
• Locations: 1 country
• Sites: 1

Brief Summary

Prostate cancer is the most common cancer among men 50 years and older and mainly affets patients 75 years old. Androgen deprivation therapy is indicatated in intermediates and high risks form of prostate cancer, in association with radiotherapy for 6 monts to 3 years. It is also indicated after surgery. Current therapies induce inhibition of sexual hormones as androgens among which testosterone. These therapies present side effects which have to be acknowledeged during the elaboration therapeutic startegies in older patients: hypogonadism induced by androgen deprivation therapy (ADT) causes loss of bone mineral density, diminution of lean body mass and increase of fat body mass. Sarcopenia is defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. In addition to aging, many factors may contribute to sarcopenia as cancer and/or ADT. This cohort study aims to evaluate risk factors associated to sarcopenia prevalence and the relationship between ADT and sarcopenia incidence, in patients 70 years or older with localized or locally advanced prostate cancer

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• Prevalence of sarcopenia in older patient with prostate cancer

  All patients are screened for sarcopenia with the SAR-F questionnaire test

  36 months

Secondary Outcomes (3)

• Evaluation of sarcopenia severity

  36 months

• Skeletal Muscular Index

  36 months

• Evaluation of sarcopenia severity

  36 months

Interventions

Prevalence of sarcopenia in older patient with prostate cancer OTHER

All patients are screened for sarcopenia with the SAR-F questionnaire test score ≥4/10 suspected of sarcopenia will undergo a dual-X-ray exam to dertemine their skeletal muscle mass and the prevalence of sarcopenia before oncological treatment.

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients 70 years or older with localized or locally advanced prostate cancer.

You may qualify if:

• Patients aged 70 years and older
• Proven localized or locally advanced prostate cancer
• Treated by radiotherapy associated to ADT
• CGA needed (screened by G8 Score ≤14)

You may not qualify if:

• Protected pateint under guardiaship
• Metastatic prostate cancer
• Patient refusal
• Patient cripled with severe dementia

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assistance Publique Hôpitaux de Marseille

Marseille, 13354, France

Location

Related Publications (1)

• Couderc AL, Villani P, Berbis J, Nouguerede E, Rey D, Rossi D, Lechevallier E, Badinand D, Bastide C, Karsenty G, Boissier R, Amichi K, Muracciole X. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial. BMC Cancer. 2022 Jan 18;22(1):78. doi: 10.1186/s12885-021-09105-8.

  PMID: 35042460 DERIVED

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Emilie Garrido-Pradalié

  Assistance Publique Hôpitaux de Marseille

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2020
• First Posted: July 23, 2020
• Study Start: December 11, 2019
• Primary Completion: September 28, 2023
• Study Completion: September 28, 2023
• Last Updated: February 4, 2026

Record last verified: 2026-02

Locations

FR (1)